Amidst business uncertainty from the West Asia conflict, more companies are choosing confidential IPO filings to protect sensitive information and gain a longer preparation window. This trend is particularly noted in sectors like pharma, fintech, and healthcare, where maintaining competitive advantage and managing regulatory challenges are crucial. “Given that there is a lot of business uncertainty arising from the West Asia crisis, this additional time is an important benefit for IPO bound companies,” said Pracheta Bhattacharya, partner, JSA Advocates & Solicitors. “Additionally, companies in niche sectors or the technology-led businesses do not want to reveal confidential performance metrics at the DRHP stage, with limited deal certainty. For them, it’s making perfect sense to go for the confidential route.” Read more
This story also appeared online
